Friends Welcomes Margaret Anderson, Edward J. Benz Jr, and Elizabeth Thompson
January 17, 2019 – Washington, DC – Friends of Cancer Research (Friends) is pleased to announce the additions of Margaret Anderson, Dr. Edward J. Benz Jr., and Elizabeth Thompson to its Board of Directors. The new members bring a wealth of experience and expertise that will help Friends further its mission to advance treatments for patients.
“We are honored to have Margaret, Ed, and Elizabeth join our Board of Directors,” said Friends’ Chair & Founder, Ellen Sigal. “With the incredible depth of knowledge and diversity of expertise each of these new board members bring will be vital to continuing to innovate for patients.”
Anderson, Dr. Benz, and Thompson join some of the most innovative leaders in the field of research and regulation on Friends’ current board.
Anderson is a managing director at Deloitte Consulting LLP where she works across the federal health, nonprofit, and life sciences sectors. She is focused on advancing treatments and interventions for patients, as well as helping to improve the outcomes and efficiency of research and delivery systems. Before joining Deloitte, Anderson was the executive director at FasterCures, a Washington, DC-based center of the Milken Institute, where she advocated for cross-sector collaboration and innovation, and engaged patients as partners. She has worked on biomedical and public health policy at the Congressional Office of Technology Assessment, Society for Women’s Health Research, and the American Public Health Association.
Dr. Benz is President and CEO emeritus of the Dana-Farber Cancer Institute, director emeritus and principal investigator of Dana-Farber/Harvard Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Cancer Center. He is also a clinical hematologist and an active NIH-funded investigator. He graduated from Harvard Medical School in 1973 and received his training at Brigham and Women’s Hospital and the National Institutes of Health.
Thompson serves as the chief executive officer of the National Osteoporosis Foundation. She is widely regarded for her 30 years of national and global leadership experience and has a track record of engaging diverse stakeholders to set a common agenda for impact, raising money for research, and advocating for evidence-based high quality and high value care. Prior to joining the National Osteoporosis Foundation, Thompson served as the President and CEO of C-Change and as President of Susan G. Komen for the Cure.
About Friends of Cancer Research
Friends of Cancer Research (Friends) drives collaboration among partners from every healthcare sector to power advances in science, policy and regulation that speed lifesaving treatments to patients. For more information, please visit www.focr.org.